NEW YORK, Feb. 25 (GenomeWeb News) - Michael Stapleton has become general manager and vice president, and Vivien Bonazzi director of research and development at Invitrogen's bioinformatics business, the company said last week.
Stapleton previously worked at Accelrys, where he was executive vice president and COO. He holds doctorate and master's degrees in chemical physics, and a bachelor's degree in chemistry from Southampton University in the UK.
Bonazzi joins Invitrogen from Celera Genomics, where she was director of product development and scientific management. She holds doctorate and master's degrees in molecular pharmacology from the University of Melbourne, and a bachelor's degree in applied science from the University of Canberra in Australia.
Steven Schiltz has become CEO, and Cheryl Janson has become director of protein crystallization at structural proteomics company Shamrock Structures, the Woodridge, Ill.-based company said last week.
Previously, Schiltz was a director of business development at MediChem Life Sciences, now a subsidiary of Decode Genetics. He holds an MBA from Lewis University and a bachelor in business administration from the University of St. Francis.
Janson joins Shamrock from GlaxoSmithKline Pharmaceuticals, where she was a senior investigator. She holds a doctorate in biochemistry from the University of Wisconsin, Madison, and a bachelor's degree in chemistry from Ohio State University.
Tom Schwei has become vice president and general manager of DNAStar of Madison, Wis. Schwei has held management positions at Promega, PanVera, and Invitrogen.
Robert Voelkner has joined InnaPhase, a Philadelphia-based LIMS provider, as director of business development, the company said on Monday. Previously, he was vice president of sales for Thermo Electron's informatics division. Prior to that, he was director of worldwide sales and marketing for Beckman Coulter's laboratory automation operations, which was acquired by InnaPhase last summer. Voelkner holds a bachelor's degree in computer science from the University of Scranton.
Stephen Readhas become interim CFO of Exact Sciences, replacing John McCarthy, who left the company "to pursue other opportunities," Exact Sciences said on Monday. Read also serves as vice president and corporate controller. Exact Sciences, based in Marlborough, Mass., is currently looking for a permanent replacement of McCarthy, who joined the company in 2000.
Sean Ekins has joined St. Joseph, Mich.-based GeneGo as vice president for computational biology, the company said on Monday. Most recently, he was associate director for computational drug discovery at Concurrent Pharmaceuticals. Ekins holds a PhD from the University of Aberdeen in the UK.
James Lewkowski has become executive vice president for Annapolis, Md.-based PharmAthene, the company said last week. He joins PharmAthene from Gene Logic, where he directed alliances with pharmaceutical companies. PharmAthene works on preventing and treating diseases associated with biological warfare.
Gregory Sloma has been appointed to the board of directors of Transgenomic, the company said yesterday. He is currently executive vice president and CFO of "a privately held electronic communications company," according to Transgenomic.
Eric Topol has joined the scientific advisory board of Perlegen, the company said last week. He is chief academic officer of The Cleveland Clinic Foundation and provost of the Cleveland Clinic Lerner College of Medicine of Case Western University.